Mazieres J, Cropet C, Montané L, Barlesi F, Souquet P, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier-Ait Oukhatar C, Blay J Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann. Oncol.. 2020;31(2):289-294. doi:10.1016/j.annonc.2019.10.022
Bianco J, Bergoglio V, Lin Y-L, Pillaire M-J, Schmitz A-L, Gilhodes J, Lusque A, Mazières J, Lacroix-Triki M, Roumeliotis T, Choudhary J, Moreaux J, Hoffmann J-S, Tourrière H, Pasero P Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nat Commun. 2019;10(1):910. doi:10.1038/s41467-019-08886-8
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Dec 17, 2019. doi:10.1172/JCI126896
Paul C, Delpech H, Haouzi D, Hamamah S, Sardet C, Fabbrizio E Coprs inactivation leads to a derepression of LINE1 transposons in spermatocytes. FEBS Open Bio. 2019;9(1):159-168. doi:10.1002/2211-5463.12562
Pujol J-L, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis M, Langlais A, Morin F, Souquet P-J A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. J Thorac Oncol. 2019;14(5):903-913. doi:10.1016/j.jtho.2019.01.008
Pujol J-L, Jean-Baptiste S, Bommart S, Roch B Synchronous multiple non-small cell lung cancers in an allograft lung recipient. Lung Cancer. 2018;124. doi:10.1016/j.lungcan.2018.07.024
Middleton G, Gridelli C, Pujol J-L, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul C, John W, Zimmermann A, Chouaki N, Paz-Ares L Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018;34(5):865-871. doi:10.1080/03007995.2018.1439462
Solassol J, Quantin X, Larrieux M, Senal R, Audran P, Grand D, Mangé A, Diamandis E, Vendrell J Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. Clin. Chem. Lab. Med.. 2018;56(9):e243-e246. doi:10.1515/cclm-2017-0967
Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas P, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell. 2018;33(2):217-228.e4. doi:10.1016/j.ccell.2017.12.014
Mancini M, Gaborit N, Mazzeo L, Romaniello D, Salame T, Lindzen M, Mahlknecht G, Enuka Y, Burton D, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter R, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. EMBO Mol Med. 2018;10(2):294-308. doi:10.15252/emmm.201708076
Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman M, Srivastava S, Ghosh S, Lindzen M, Salame T, Onn A, Bar J, Yarden Y A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clin. Cancer Res.. Jul 02, 2018. doi:10.1158/1078-0432.CCR-18-0450
Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO Mol Med. 2017;9(2):238-250. doi:10.15252/emmm.201606646
Chebli K, Papon L, Paul C, Garcel A, Campos N, Scherrer D, J Ehrlich H, Hahne M, Tazi J The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages. Sci Rep. 2017;7(1):4860. doi:10.1038/s41598-017-04071-3
Langer C, Paz-Ares L, Wozniak A, Gridelli C, de Marinis F, Pujol J-L, San Antonio B, Chen J, Liu J, Oton A, Visseren-Grul C, Scagliotti G Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. Clin Lung Cancer. 2017;18(5):489-496. doi:10.1016/j.cllc.2017.04.003
Basse C, Thureau S, Bota S, Dansin E, Thomas P-A, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol. 2017;12(11):1715-1722. doi:10.1016/j.jtho.2017.07.023
Bommart S, Berthet J, Durand G, Pujol J, Mathieu C, Marty-Ané C, Kovacsik H Imaging of postoperative complications following surgery for lung cancer. Diagn Interv Imaging. 2017;98(1):11-20. doi:10.1016/j.diii.2015.06.022
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y-C, Karapetis C, Hiret S, Ostoros G, Kubota K, Gray J, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis P, Özgüro?lu M Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med.. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937
Vendrell J, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol J-L, Brousset P, Rouquette I, Solassol J Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):12510. doi:10.1038/s41598-017-12679-8
Casas-Tintó S, Maraver A, Serrano M, Ferrús A Troponin-I enhances and is required for oncogenic overgrowth. Oncotarget. 2016;7(33):52631-52642. doi:10.18632/oncotarget.10616
Pujol J, De Pas T, Rittmeyer A, Vallieres E, Kubisa B, Levchenko E, Wiesemann S, Masters G, Shen R, Tjulandin S, Hofmann H, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves P, Louahed J, Brichard V, Lehmann F Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Aug 17 2016. doi:10.1016/j.jtho.2016.08.120
Barlesi F, Mazieres J, Merlio J, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier P, Lamy R, Beau-Faller M, Pujol J, Sabourin J, Penault-Llorca F, Denis M, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria J, Zalcman G, Biomarkers France c Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. Jan 14 2016. doi:10.1016/S0140-6736(16)00004-0
Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Salle F, Mazieres J, Quoix E, Pujol J, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. Oncotarget. Dec 19 2016. doi:10.18632/oncotarget.14025
Pujol J Is Weight Loss a Loss of Chance in Patients Receiving Chemoradiotherapy?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016;11. doi:10.1016/j.jtho.2016.04.010
Makinson A, Eymard-Duvernay S, Raffi F, Abgrall S, Bommart S, Zucman D, Valour F, Cheret A, Poizot-Martin I, Duvivier C, Mauboussin J, Bonnet F, Tattevin P, Reynes J, Le Moing V, Anrs Ep Hiv Chest study Team Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. Aids. 2016;30. doi:10.1097/QAD.0000000000000943
Rivera-Torres J, Guzman-Martinez G, Villa-Bellosta R, Orbe J, Gonzalez-Gomez C, Serrano M, Diez J, Andres V, Maraver A Targeting gamma-secretases protect against angiotensin II-induced cardiac hypertrophy. Journal of hypertension. 2015;33. doi:10.1097/HJH.0000000000000463
Institut de Recherche en Cancérologie de
